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and Lecia V. Sequist, MD, MPH†
Introduction: Among patients with non-small cell lung cancer
(NSCLC), patients aged 80 or older have inferior survival. Treat-
ment practices in this patient population are poorly described. In this
report, we describe the treatment of a population of very elderly
patients with NSCLC at a large teaching hospital.
Methods: A retrospective chart review was performed of 111
outpatients with NSCLC aged 80 or older. Patient treatment regi-
mens were evaluated for consistency with contemporaneous stage-
specific guideline-recommended therapy (GRT). Attention was paid
to how patient characteristics and attitudes influence therapy deci-
sions.
Results: Patients characteristics included median age of 82.6 years
(range, 80–92), 30% stage I–II , 39% stage IV, 59% performance
status 0–1, 25% performance status2 (performance status unavail-
able for 15%). Eighty-four percent of the patients received some
form of antineoplastic therapy, and 11% were treated with best
supportive care alone. Of 34 patients with localized disease, 53%
underwent tumor resection and 38% received definitive radiation. Of
70 patients with stage III or IV disease, 36% received cytotoxic
chemotherapy and 27% received oral targeted therapy alone. Thirty-
two percent of patients received the stage-specific GRT. Of the
patients who did not receive GRT, 26% electively refused the
offered GRT and 74% were not offered GRT.
Conclusions: The vast majority of octogenarian patients with
NSCLC receive antineoplastic therapy, but only one third of this
population receives stage-specific GRT. Although many patients
choose aggressive therapies, a small but clinically significant portion
chose not to receive the offered GRT. More data are needed on
appropriate therapy recommendations for this patient population.
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Lung cancer is the leading cause of cancer death in theUnited States, responsible for nearly one third of all
cancer deaths1,2; the majority of cases are non-small cell lung
cancer (NSCLC). With a median age of incidence of 70 years,
lung cancer is increasingly being recognized as a disease of
the elderly.2 Since a landmark article by Hutchins et al.3
describing the underrepresentation of elderly patients in can-
cer clinical trials, a number of studies have explored the
treatment of lung cancer in patients aged 70 and older. Most
of these have been subset analyses of the elderly population
within a larger study, although some trials have been de-
signed as elderly specific. From this literature, we know that
selected elderly patients can tolerate surgery, radiation, and
chemoradiation for local and locally advanced disease, as
reviewed by Hurria and Kris.4 A large randomized trial
demonstrated that elderly patients achieve a clear survival
benefit from single-agent chemotherapy for advanced disease
compared with best supportive care (BSC),5 and selected
elderly patients can tolerate and benefit from more aggressive
combination chemotherapy regimens.6–8
However, the treatment of the very elderly with lung
cancer, those age 80 or older, remains poorly described. A
recent study of the national Surveillance, Epidemiology and
End Results (SEER) database9 found that lung cancer patients
older than the age of 80 had an inferior 5-year survival rate
(8.3%) compared with younger patients (16.2%, p 0.0001),
controlling for stage, gender, and race. It also demonstrated that
in practice, fewer of these very elderly NSCLC patients receive
surgery or radiation treatments compared with younger patients.
An earlier analysis of NSCLC patients in the SEER database
found that the rate of receiving guideline-recommended therapy
(GRT) was lower among patients aged 80 and older (33%) than
among patients aged 50 to 59 (66%).10
There are only limited data available supporting spe-
cific therapies for NSCLC patients older than the age of 80.
Recent surgical literature is optimistic about offering curative
surgery to appropriately selected NSCLC patients aged 80 or
older.11–13 In the sole published clinical trial of chemotherapy
for advanced disease specifically performed in patients aged
80 and older,14 20 treatment-naive patients received vinorel-
bine plus gemcitabine and had a median survival of 10
months, comparable with results expected with chemotherapy
in younger patients.
In this report, we describe the experience of NSCLC
patients aged 80 or older at a major teaching hospital. In
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particular, we compare treatments received with those thera-
pies that are recommended according to current practice
guidelines. Furthermore, we investigate the specific factors
that influence treatment selection in this age group.
PATIENTS AND METHODS
A comprehensive database of patients evaluated be-
tween April 2001 and September 2005 at the Center for
Thoracic Cancer at the Massachusetts General Hospital Can-
cer Center was queried to identify patients with lung cancer
aged 80 or older, generating an initial sample of 144 patients.
This sample was reviewed to exclude patients with non-
NSCLC tumor histology (small-cell lung cancer, mesotheli-
oma, nonbronchogenic primary, unknown primary), and age
at presentation younger than 80. As our goal population was
outpatient NSCLC patients, patients were excluded if they
received inpatient consultation without outpatient follow-up.
Our final sample of 111 patients consisted of outpatients with
NSCLC presenting to our cancer center at the age of 80 or
older. Patients presenting for second-opinion consultation
only were included in the study, although complete data on
their course of treatment were not always available.
Medical records were reviewed according to an insti-
tutional review board–approved protocol and a single physi-
cian collected all data. Data were collected on patient demo-
graphics and medical history, treatments administered, and
tolerability of treatment. Tumor stage was determined as per
the American Joint Committee on Cancer guidelines for lung
cancer staging, 6th edition.15 When available, additional de-
tails were collected regarding the medical decision-making
process, including which treatments were offered to each
patient, reasons why physicians offered specific treatments,
and reasons why patients chose specific treatments.
A standard, stage-specific GRT was determined from
practice guidelines and medical literature.16,17 Table 1 details
stage-specific GRT (shown in boldface type). For stage IA
disease, anatomic resection with lobectomy or pneumonec-
tomy was considered GRT. (Recent literature has suggested
the equivalence of anatomic and limited resection in elderly
patients18; however, this has not been incorporated into prac-
tice guidelines.) GRT for stage IB and II tumors depended on
the time of patient presentation because the use of adjuvant
platinum-based chemotherapy became standard at our insti-
tution after the presentation of the International Adjuvant
Lung Cancer Trial data in mid-2003. For this reason, ana-
tomic resection was considered GRT before mid-2003, at
which point GRT changed to require adjuvant chemotherapy
following resection.19,20 (Data suggesting that adjuvant che-
motherapy is poorly tolerated by elderly patients was pub-
lished after the completion of our study period.21) For locally
advanced disease (stage III, excluding malignant pleural
effusion), concurrent chemoradiation therapy, with or without
surgical resection, was considered GRT. For advanced dis-
ease (stage IV or stage IIIB with malignant effusion), any
cytotoxic chemotherapy regimen was considered GRT for
these elderly patients.16 Each of our patients’ treatment reg-
imens over time, including treatments received immediately
before presentation at our cancer center, was evaluated for
consistency with GRT.
Tolerance of the various treatment modalities among
very elderly NSCLC patients was grossly assessed by exam-
ining the incidence of severe postoperative morbidity, the
30-day postoperative mortality, and the fraction of patients
able to successfully complete their prescribed radiation
course or the first two cycles of a systemic therapy course.
The frequency of dose adjustments for toxicity was also
recorded. Descriptive statistics regarding the distribution of
observed treatments were prepared. We fit a multivariable
logistic regression model to determine the independent asso-
ciation between age, performance status (PS), and receiving
GRT.
RESULTS
The characteristics of the 111 patients studied are
summarized in Table 2. The age at presentation ranged from
80 to 92 years, with a median age of 82.6. Fifty-nine percent
of patients had an Eastern Cooperative Oncology Group PS
TABLE 1. Most Aggressive Treatment Administered by
Tumor Stage (n  104)
Stage Treatment
Patients,
No. (%)
All stages 104
Guideline recommended therapy 33 (31.7)
IA 17
Lobectomy 3 (17.6)
Limited resection 5 (29.4)
Definitive radiation 9 (52.9)
Best supportive care 0 (0.0)
IB and II 17
Lobectomy with adjuvant chemotherapy 0 (0.0)
Lobectomy alone (before IALT study) 4 (23.5)
Lobectomy alone (after IALT study) 4 (23.5)
Limited resection alone 2 (11.8)
Definitive radiation alone 3 (17.6)
Chemoradiation 1 (5.9)
Palliative therapies only 2 (11.8)
Best supportive care 1 (5.9)
IIIA and IIIB 20
Neoadjuvant chemoradiation with resection 1 (5.0)
Chemoradiation with platinum doublet 6 (30.0)
Definitive radiation alone 6 (30.0)
Palliative radiation only 3 (15.0)
Best supportive care 4 (20.0)
IV (including IIIB with malignant effusion) 50
Platinum doublet 3 (6.0)
Single-agent chemotherapy 15 (30.0)
Isolated cranial metastectomy 1 (2.0)
Targeted therapy 19 (38.0)
Palliative radiation only 6 (12.0)
Best supportive care 6 (12.0)
Analysis excludes three patients for whom stage data were unavailable and four
additional patients for whom treatment data were unavailable. Guideline-recommended
therapies appear in bold. IALT, International Adjuvant Lung Cancer Trial.
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of 0 or 1 when initially evaluated, although 15% of patients
had no PS recorded. 26% of patients had a Charlson comor-
bidity index score of 0, 42% had a Charlson index of 1–2, and
32% had a Charlson index of 3 or more. Thirty-one percent of
patients had stage I or II disease at completion of staging, and
39% had metastatic disease.
Median duration of follow-up was 8.4 months (range,
0–90). The treatments administered during the study period
are depicted in Table 3. Overall, 84% of patients received
some form of antineoplastic therapy, whereas 11% received
BSC only (treatment data unavailable for six of 111 patients).
Nineteen (17%) patients underwent surgical resection of their
primary tumor, with ages ranging from 80 to 86 years
(median, 81.7). Radiation therapy was the most common
therapy administered overall, with 52 (47%) patients treated.
Approximately half of the radiation regimens were palliative
therapy to the chest, central nervous system, or bones. Sys-
temic anticancer therapies were administered to 55 (50%)
patients overall, with 30 (27%) patients undergoing treatment
with at least one cytotoxic chemotherapy regimen, and 39
(35%) patients treated with an oral small molecule epidermal
growth factor receptor (EGFR) targeted agent. For 25 (23%)
patients, oral targeted therapy was the only antineoplastic
therapy they received during the study. Among the 30 che-
motherapy-treated patients, 11 (37%) received a platinum-
based combination regimen; 21 (70%) were treated with a
solitary regimen or “line” of therapy, and four (13%), four
(13%), and one (3%) patients received two, three, and four
lines of chemotherapy each, respectively.
Examining the treatments given to patients by stage at
presentation (Table 1), we found that among the 34 patients
with localized disease (stages I–II), 18 (53%) underwent
surgical resection, 12 (35%) were deemed medically inoper-
able, and another four (12%) patients refused resection. Of
the patients offered resection, 86% underwent the surgery and
14% declined. Eleven (61%) of the 18 thoracic surgeries
performed were anatomic resections, all of which were lo-
bectomies, and the remaining seven procedures were limited
resections. There were no pneumonectomies performed in
this cohort. None of the surgical patients received adjuvant
TABLE 2. Patient Characteristics (n  111)
Characteristic Patients, No. (%)
Gender
Male 55 (49.5)
Female 56 (50.5)
Age at presentation, yr
80–81 37 (33.3)
82–83 26 (24.4)
84–85 25 (22.5)
86–87 14 (12.6)
88–89 6 (5.4)
90–92 3 (2.7)
Median 82.6
Performance status
0 27 (24.3)
1 39 (35.1)
2 22 (19.8)
3 6 (5.4)
Not recorded 17 (15.3)
Charlson comorbidity index
0 29 (26.1)
1–2 47 (42.3)
3 35 (31.5)
Smoking history
Any smoking history 102 (91.9)
Nonsmoker 9 (8.1)
Tumor histology
Adenocarcinoma 61 (55.0)
Squamous cell carcinoma 21 (18.9)
Other 23 (20.7)
NSCLC NOS 6 (5.4)
Stage
IA 17 (15.3)
IB 11 (9.9)
IIA 1 (0.9)
IIB 5 (4.5)
IIIA 13 (11.7)
IIIB, without malignant effusion 10 (9.0)
IIIB, with malignant effusion 8 (7.2)
IV 43 (38.7)
Not recorded 3 (2.7)
NSCLC NOS, non-small cell lung cancer not otherwise specified.
TABLE 3. Treatments Administered during the Study Period
by Modality (n  111)
Treatment received Patients, No. (%)
Any antineoplastic therapy 93 (83.8)
Best supportive care only 12 (10.8)
Unknown 6 (5.4)
Any resection of primary tumor 19 (17.1)
Lobectomy 11 (9.9)
Limited resection (wedge or segmental) 7 (6.3)
Resection after neoadjuvant chemoradiation 1 (0.9)
Any radiotherapy 52 (46.8)
Definitive radiotherapy 19 (17.1)
Palliative radiotherapy 27 (24.3)
Chemoradiation 9 (8.1)
Any cytotoxic chemotherapy 30 (27.0)
Carboplatin/paclitaxel 10 (9.0)
Carboplatin/docetaxel 1 (0.9)
Vinorelbine 16 (14.4)
Docetaxel 5 (4.5)
Paclitaxel 3 (2.7)
Gemcitabine 3 (2.7)
Pemetrexed 5 (4.5)
Other (experimental therapies) 2 (1.8)
Any targeted therapy 39 (35.1)
Erlotinib 8 (7.2)
Gefitinib 33 (29.7)
Note that some patients received multiple treatments.
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chemotherapy. Of the four patients who underwent resection
after presentation of the International Adjuvant Lung Cancer
Trial results,19 two were offered adjuvant chemotherapy but
chose not to receive it, and two were not offered it due to PS
or age. Of the 16 nonsurgical patients with limited disease, 13
(81%) received definitive radiation therapy, one of these with
concurrent chemotherapy.
Treatment data were available for 20 of 23 patients with
locally advanced disease (stage III, excluding malignant pleu-
ral effusion). One patient underwent trimodality therapy con-
sisting of neoadjuvant radiation and concurrent carboplatin
and paclitaxel, followed by surgical resection. Twelve (60%)
patients received definitive radiation, including six patients
treated with concurrent chemotherapy (with carboplatin and
paclitaxel) and six patients treated with radiation only. None
of the patients were given chemoradiation in a sequential
fashion or were given platinum-based chemotherapy alone.
Three (15%) patients underwent radiation with palliative
intent and four (20%) were treated with BSC only.
Treatment data were available for 50 of 51 patients who
presented with advanced disease. Eighteen (36%) patients
were treated with cytotoxic chemotherapy, including three
(6%) with a platinum-based combination regimen and 15
(30%) with a monotherapy regimen. Three of the 18 chemo-
therapy patients received an oral EGFR inhibitor initially
before later receiving cytotoxic chemotherapy. Nineteen pa-
tients with advanced disease (38%) were treated with oral
EGFR-targeted agents as their only systemic therapy, with a
large portion of these (47.3%) having not been offered che-
motherapy due to PS, age, or unspecified reasons. One patient
underwent an isolated cranial metastectomy and no chemo-
therapy. Six (12%) patients were treated with BSC alone. Of
the patients who presented with stage III or IV disease who
were offered cytotoxic chemotherapy, 68% underwent the
treatment, and 32% refused it.
When considering the stage-specific GRT as we defined
it, 33 of 104 very elderly NSCLC patients (32%) received the
appropriate GRT. Patients receiving GRT were aged 80 to 87
years (median, 82.1) and had a PS of 0 or 1 with the exception
of one PS 2 patient. Multivariate analysis demonstrated that
independent predictors for failing to receive GRT included
PS 2 (OR  17.1; 95% confidence interval [CI]: 2.2–135)
and age 85 or older (OR  4.8; 95% CI: 1.0–23.4). Factors
not associated with receiving GRT were Charlson index (OR
1.3; 95% CI: 0.9–1.7), gender (OR  0.8; 95% CI: 0.3–1.7),
and tumor stage (OR 0.9; 95% CI: 0.8–1.1). Of the patients
not receiving GRT, 26% refused it, 48% were not offered it
due to PS or comorbid conditions, and 26% were not offered
it due to age or reasons not explicitly stated in the medical
record. Table 4 provides additional details about therapy
decision making.
The majority of very elderly NSCLC patients were able
to tolerate their respective treatments well (Table 5). Of the
16 surgical patients for whom data were available, four (25%)
suffered serious postoperative complications, including one
(6%) who died within 30 days of cardiogenic shock. Radio-
therapy was generally well tolerated with 84% of patients
completing their prescribed course of therapy; 96% of defin-
itive regimens and 72% of palliative regimens were com-
pleted. Of 45 cytotoxic chemotherapy regimens administered,
33 (73%) were tolerated for two complete cycles until
planned restaging examinations, whereas 10 (22%) were
aborted before the first planned restaging examination (data
unavailable for two treatment regimens). Nineteen of the 33
(58%) completed chemotherapy regimens were dose or
schedule adjusted for toxic adverse events. Of 41 targeted
therapy regimens initiated, 31 (76%) were continued for at
least 2 months.
DISCUSSION
This study examined the outpatient treatment patterns
of NSCLC patients aged 80 years and older evaluated at an
academic general hospital cancer center and found that the
vast majority of patients (84%) receive some form of anti-
neoplastic therapy. These data suggest that the historical
notion that advanced age should automatically preclude con-
sideration of cancer treatment is falling out of practice.
However, only 32% of patients received the stage-specific
GRT, which may offer insight into why very elderly patients
TABLE 4. Reasons Why Guideline-Recommended Therapy Was Not Received (n  69)
Stage
IA IB/II IIIA/IIIB IVa
Reason All Stages Lobectomy Lobectomy  Adjuvant Chemob Chemoradiation Cytotoxic Chemo
Therapy not offered 51 (73.9%) 12 9 10 20
PS/comorbidities 33 (47.8%) 7 5 8 13
Age 4 (5.8%) 0 2 1 1
Reason not specified 14 (20.3%) 5 2 1 6
Patient preference 18 (26.1%) 2 4 4 8
No surgery 3 (4.3%) 2 1 0 0
No chemo 13 (18.8%) 0 2 3 8
BSC 2 (2.9%) 0 1 1 0
Analysis excludes patient for whom data were unavailable. PS, performance status; BSC, best supportive care.
a Includes stage IIIB with malignant pleural effusion.
b For stages IB and II, resection and adjuvant chemotherapy were considered GRT only after the IALT data were presented in 2003.
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with NSCLC have inferior survival compared with younger
patients. Multiple factors influenced the treatment practices
observed, including patient health, physician attitudes, and
patient preferences.
Our data on guideline adherence are notably different
from the findings of Potosky et al.,10 although our definitions
of GRT are comparable. Compared with their study of the
SEER database in 1996, we observed a similar overall per-
centage of octogenarians receiving GRT, but our cohort
treated largely between 2001 and 2005 included fewer pa-
tients with localized disease receiving GRT and more patients
with stage III or IV disease receiving GRT. Specifically, in
our single-center cohort, 21% of very elderly patients with
stage I and II NSCLC received strict GRT (a definition that
included adjuvant chemotherapy), while 32% had anatomic
lobectomies (the recommended therapy from the SEER
study); in the SEER cohort, 55% of very elderly patients
underwent lobectomy or pneumonectomy. In our cohort, 35%
and 38% of stage III and IV patients, respectively, were
treated with GRT compared with 21% and 16% of stage III
and IV patients, respectively, in the SEER cohort. The trend
toward a decrease in GRT for localized disease at our single-
center cohort is somewhat surprising as we are an academic
cancer center with a strong surgical tradition. This observed
trend may be due to several factors including our nearly
universal use of sensitive mediastinal staging modalities such
as positron emission tomography and mediastinoscopy,
which can shift patients from stage I–II diagnoses to stage III
NSCLC, and our catchment population of medically complex
patients, as evidenced by the 35% of patients with localized
disease deemed medically inappropriate for surgery. The
trend toward increased administration of GRT for very el-
derly NSCLC patients with stage III and IV disease in our
cohort compared with the SEER study is consistent with
comparing the practice of an academic referral center to a
national database, but may also suggest that increased aware-
ness of the issues of caring for elderly cancer patients and
improvement in the efficacy of systemic NSCLC treatments
over the past decade are leading to changes in patient and
physician attitudes toward making treatment decisions in this
age group.
Our finding that 32% of patients aged 80 or older
received GRT is inherently dependent on which therapy we
consider “recommended” for this age population; these rec-
ommendations are largely inferred from data obtained in
studies of younger patients. Defining GRT in patients aged 80
years and older is challenging given the scarcity of outcomes
data in the very elderly population, in part due to the partic-
ular difficulty accruing very elderly patients in clinical tri-
als.7,22 If our definition of GRT for very elderly patients were
broadened somewhat to include limited resections or to in-
clude resections without adjuvant chemotherapy, both of
which have been suggested by some data,18,23 then a greater
portion of our patients would have received GRT. More
investigation of survival and quality-of-life outcomes is
needed to determine which therapies that we normally offer
younger patients should be withheld from the very elderly.
Although both age and PS influenced whether a patient
received GRT, PS was a much stronger predictor in our
multivariable analysis (OR  17.1 and 4.8 for PS and age,
respectively). This is consistent with our finding that the most
common documented reason for not receiving GRT was PS
or comorbid disease. The Charlson comorbidity index was
not found to correlate with receiving GRT in this cohort,
although it has previously been found to correlate with
outcomes in surgical lung cancer patients of all ages.24 It is
reassuring that PS is weighed heavily in patients of this age
group because PS is one of the strongest known predictors of
survival and therapy tolerance in NSCLC. Still, we found that
8% of the time that a patient was not offered GRT, the
physician noted age as the primary reason. An additional 14
patients were not offered GRT due to unspecified reasons,
and it is likely that age played a role in some of these
decisions. These 14 cases consisted largely of limited resec-
tions being performed rather than anatomic (seven cases) and
patients with advanced disease receiving targeted therapy
rather than chemotherapy (five patients). We are optimistic
that studies such as ours will influence a decrease in the
frequency with which oncologists make treatment decisions
based primarily on age.
Our data are consistent with previous findings that
elderly patients desire aggressive therapy as often as younger
patients.25 Fifty-three percent of patients with localized dis-
ease underwent resection, and of 30 patients receiving che-
motherapy, 30% went on to receive a second regimen and one
patient received four different regimens (as well as receiving
erlotinib). Compared with the historical experience from the
University of Tsukuba in Japan, which found that 25 of 50
octogenarians with NSCLC received BSC alone,26 we ob-
served that only 11% of very elderly patients were treated
with only BSC. This change suggests that offering aggressive
palliative therapies to octogenarians has gained increased
acceptance at academic centers over the past decade.
TABLE 5. Tolerability of Therapy Received
Therapy Modality and Tolerability/Toxicity No. (%)
Surgical resections 16
Severe morbidity 4 (25.0)
Small bowel obstruction 1
Shock 3
30-day mortality 1a (6.3)
Radiation therapy regimens 57
Completed course of radiation 48 (84.2)
Cytotoxic chemotherapy regimens 45
2 cycles completed 33 (73.3)
Did not complete 2 cycles of therapy 10 (22.2)
Data unavailable 2 (4.4)
Targeted therapy regimens 41
2 mo completed 31 (75.6)
Did not complete 2 mo of therapy 9 (22.0)
Data unavailable 1 (2.4)
Cases excluded from analysis if tolerability/toxicity data not available.
a Secondary to postoperative myocardial infarction and cardiogenic shock.
Journal of Thoracic Oncology • Volume 2, Number 11, November 2007 Non-small Cell Lung Cancer in Octogenarians
Copyright © 2007 by the International Association for the Study of Lung Cancer 1033
In addition, this study is the first to our knowledge
that documents the clinically significant portion of octo-
genarian patients who elect to decline therapies that their
doctor has recommended. Fourteen percent of patients who
were offered curative surgery refused it, and 24% of
patients with stage III or IV disease refused chemotherapy.
One patient, an 81-year-old woman with stage II cancer,
refused resection and radiotherapy, not wishing to undergo
life-prolonging procedures; she did, however, wish im-
prove her quality of life and underwent a total hip replace-
ment, living another 11 months after the surgery. However,
our findings were noted in patients presenting to an oncol-
ogy clinic and may underestimate the amount of disincli-
nation toward therapy in this age group, considering the
additional population of patients with NSCLC who do not
obtain an oncology consultation.
Oral targeted therapy was notably more popular than
cytotoxic chemotherapy in this patient population. More than
one fifth of patients (23%) received targeted therapy as their
only antineoplastic therapy, due to either poor PS or a desire
for “a minimalistic approach to. . .therapy” or a desire to
“return to [a] normal schedule.” Our academic cancer center
has a particular research focus on EGFR inhibitor therapy,
which may have increased the popularity of these therapies in
our study. However, it should be noted that only three of 39
patients receiving oral EGFR therapy were participating in
clinical trials. Although more patients in this study received
gefitinib, we anticipate that erlotinib will increase in popu-
larity given recent data.27,28 More recently, a phase II trial of
first-line erlotinib in elderly patients showed a median overall
survival of 11 months,29 suggesting that comparison of erlo-
tinib to chemotherapy for elderly patients will need to be
pursued further in a randomized fashion.
Chemotherapy was slightly less well tolerated in our
patients than in published elderly chemotherapy trials. Al-
though 22% of our patients stopped chemotherapy before
initial restaging, single-agent studies have shown that 9%5
and 11%30 of patients aborted therapy before initial restaging.
Of the patients who did receive two full cycles of therapy, a
significant proportion (58%) required dose interruption or
adjustment. These findings are not surprising for very elderly
patients and demonstrate the flexibility required when deliv-
ering cytotoxic chemotherapy to this age group.
In summary, we found that our population of patients
with NSCLC aged 80 years or older received antineoplastic
therapy 84% of the time, however, received GRT only 32%
of the time. Very elderly patients have diverse attitudes
toward cancer treatment. Although some desire aggressive
treatment modalities, a significant portion decline therapies
offered by their oncologist; thus, treatment decisions must be
individualized to their life expectancies and life goals. Due to
the heterogeneous nature of our study population’s baseline
health and treatment regimens, we were not able to evaluate
patient survival or tumor response. It is hoped that our data
will encourage increased study of both the appropriate treat-
ment algorithms for very elderly NSCLC patients and the
attitudes toward treatment by both physicians and patients,
leading to the development of improved care for this growing
patient population.
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